Ronald T Ingram

US Patent:

8357402, Jan 22, 2013

Filed:

Jul 5, 2011

Appl. No.:

13/176174

Inventors:

Ronald T. Ingram - Encinitas CA, US
Jignesh B. Patel - Newtown PA, US
Timothy J. Pryor - Yardley PA, US

Assignee:

Integra LifeSciences Corporation - Plainsboro NJ

International Classification:

A61K 9/50
A61K 38/39
A61K 47/48

US Classification:

424499, 514 172

Abstract:

This invention relates to a flowable collagen/glycosaminoglycan (GAG) material including particles of collagen/GAG matrix that, when hydrated, can be effectively delivered to wounds having varying depths and geometries. The flowable collagen/GAG matrix allows a more intimate contact between the wound matrix and the wound bed, and provides a structural framework that serves as a scaffold for cell ingrowth.

US Patent:

7993679, Aug 9, 2011

Filed:

Sep 19, 2008

Appl. No.:

12/233936

Inventors:

Ronald T. Ingram - Encinitas CA, US
Jignesh B. Patel - Newtown PA, US
Timothy J. Pryor - Yardley PA, US

Assignee:

Integra LifeSciences Corporation - Plainsboro NJ

International Classification:

A61K 9/50
A61K 38/39
A61K 47/48

US Classification:

424499, 514 172

Abstract:

This invention relates to a flowable collagen/glycosaminoglycan (GAG) material including particles of collagen/GAG matrix that, when hydrated, can be effectively delivered to wounds having varying depths and geometries. The flowable collagen/GAG matrix allows a more intimate contact between the wound matrix and the wound bed, and provides a structural framework that serves as a scaffold for cell ingrowth.

US Patent:

20070161109, Jul 12, 2007

Filed:

Jan 12, 2007

Appl. No.:

11/622695

Inventors:

Simon Archibald - Pennington NJ, US
Mark Spilker - Cranbury NJ, US
Ronald Ingram - Encinitas CA, US
Jeffrey Brittan - Encinitas CA, US

Assignee:

Integra LifeSciences Corporation - Plainsboro NJ

International Classification:

C12N 5/00

US Classification:

435404000

Abstract:

A matrix for tissue growth includes: (a) a first layer including a first assembly of collagen fibers; (b) a plurality of projections on a top surface of the first layer; and (c) a second layer bonded to a bottom portion of the first layer and including a second assembly of collagen fibers, wherein the second layer has a lower density than the first layer, and the matrix includes pores effective to support cell growth into the matrix. A method for providing the matrix is also described.

US Patent:

20100016967, Jan 21, 2010

Filed:

Jul 10, 2009

Appl. No.:

12/501089

Inventors:

Jignesh B. Patel - Newtown PA, US
Karishma Vohra - Cherry Hill NJ, US
Namrata Desai - Bridgewater NJ, US
Ronald T. Ingram - Encinitas CA, US
Mark Spilker - Cranbury NJ, US
Timothy J. Pryor - Yardley PA, US

International Classification:

A61F 2/28
B29C 69/00
B32B 37/02

US Classification:

623 1611, 264241, 156192

Abstract:

Biocompatible, resorbable medical implants and related methods are disclosed in which the implant can be made of a collagen matrix for filling a space after partial or total resection of the trapezium bone of the wrist. The resorbable medical implant can include a plurality of surface projections, and the collagen matrix can be folded or spirally wound about itself to form a spiral roll.

US Patent:

57927456, Aug 11, 1998

Filed:

Apr 12, 1995

Appl. No.:

8/421697

Inventors:

Soan Cheng - San Diego CA
Ronald Ingram - Oceanside CA
Daniel Mullen - San Diego CA
Juerg F. Tschopp - San Diego CA

Assignee:

La Jolla Cancer Research Center - La Jolla CA

International Classification:

A61K 3808
A61K 3812
C07K 706
C07K 754

US Classification:

514 11

Abstract:

The present invention provides Arg-Gly-Asp peptides that can alter the binding of osteoclasts to a matrix such as bone or can selectively alter integrin receptor binding. The invention also provides methods of using the Arg-Gly-Asp peptides to alter. alpha. sub. v. beta. sub. 3 integrin receptor-mediated binding of a cell such as an osteoclast, endothelial cell or smooth muscle cell to a matrix. The invention further provides methods for ameliorating the severity of a pathology characterized, in part, by an undesirable level of bone resorption, angiogenesis or restenosis in a subject.

US Patent:

57599963, Jun 2, 1998

Filed:

Apr 12, 1995

Appl. No.:

8/421702

Inventors:

Soan Cheng - San Diego CA
Ronald Ingram - Oceanside CA
Daniel Mullen - San Diego CA
Juerg F. Tschopp - San Diego CA

Assignee:

La Jolla Cancer Research Center - La Jolla CA

International Classification:

A61K 3808
A61K 3810
A61K 3812
A61K 3816

US Classification:

514 11

Abstract:

The present invention provides Arg-Gly-Asp peptides that can alter the binding of osteoclasts to a matrix such as bone or can selectively alter integrin receptor binding. The invention also provides methods of using the Arg-Gly-Asp peptides to alter. alpha. sub. v. beta. sub. 3 integrin receptor-mediated binding of a cell such as an osteoclast, endothelial cell or smooth muscle cell to a matrix. The invention further provides methods for ameliorating the severity of a pathology characterized, in part, by an undesirable level of bone resorption, angiogenesis or restenosis in a subject.

US Patent:

58078193, Sep 15, 1998

Filed:

Apr 12, 1995

Appl. No.:

8/421698

Inventors:

Soan Cheng - San Diego CA
Ronald Ingram - Oceanside CA
Daniel Mullen - San Diego CA
Juerg F. Tschopp - San Diego CA

Assignee:

La Jolla Cancer Research Center - La Jolla CA

International Classification:

A61K 3808
A61K 3810
A61K 3812
A61K 3816

US Classification:

514 11

Abstract:

The present invention provides Arg--Gly--Asp peptides that can alter the binding of osteoclasts to a matrix such as bone or can selectively alter integrin receptor binding. The invention also provides methods of using the Arg--Gly--Asp peptides to alter. alpha. sub. V. beta. sub. 3 integrin receptor-mediated binding of a cell such as an osteoclast, endothelial cell or smooth muscle cell to a matrix. The invention further provides methods for ameliorating the severity of a pathology characterized, in part, by an undesirable level of bone resorption, angiogenesis or restenosis in a subject.

US Patent:

58498656, Dec 15, 1998

Filed:

Apr 12, 1995

Appl. No.:

8/421695

Inventors:

Soan Cheng - San Diego CA
Ronald Ingram - Oceanside CA
Daniel Mullen - San Diego CA
Juerg F. Tschopp - San Diego CA

Assignee:

La Jolla Cancer Research Foundation - San Diego CA

International Classification:

A61K 3808
C07K 706
C07K 707
C07K 754

US Classification:

530317

Abstract:

The present invention provides Arg-Gly-Asp peptides that can alter the binding of osteoclasts to a matrix such as bone or can selectively alter integrin receptor binding. The invention also provides methods of using the Arg-Gly-Asp peptides to alter. alpha. sub. v. beta. sub. 3 integrin receptor-mediated binding of a cell such as an osteoclast, endothelial cell or smooth muscle cell to a matrix. The invention further provides methods for ameliorating the severity of a pathology characterized, in part, by an undesirable level of bone resorption, angiogenesis or restenosis in a subject.